Why Parkinson's disease trial monitoring matters
Parkinson's disease is one of the most active areas in neurology drug development, with hundreds of active trials on ClinicalTrials.gov spanning disease modification, symptomatic relief, and emerging modalities including gene therapy and cell-based approaches. The pipeline has accelerated significantly as alpha-synuclein biology, LRRK2 inhibition, and GBA1 pathways have matured as targets.
Key signals that Parkinson's professionals track:
- New neuroprotective and disease-modifying programs targeting alpha-synuclein aggregation, LRRK2 inhibition, and mitochondrial dysfunction
- GBA1-positive patient subpopulation trials as precision medicine approaches advance
- Gene therapy programs (AAV-based) entering Phase 1/2 first-in-human studies
- Non-motor symptom trials (cognitive decline, depression, autonomic dysfunction)
- Status changes: trials beginning to recruit or advancing from Phase 2 to Phase 3
- Competitive pipeline updates from major CNS-focused sponsors
Get daily Parkinson's disease trial digest
Set your profile once. Receive a clean digest every morning with new PD trials and updates matching your criteria.
Get the Free DigestA primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001)… NCT06482268 | Primary completion moved at least 2 years 10 months later Primary endpoint reworded | Recruiting |
61 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| 18F-mFBG Cardiac Uptake With Lewy Body Dementia NCT07176286 | Oct 30, 2026 · Estimated | Phase 2 |
20 more on the Completions page. See the calendar →
What DataLookout monitors for Parkinson's disease
DataLookout pulls directly from the ClinicalTrials.gov API every day. For a Parkinson's watch profile, you can configure:
- Condition keywords: "Parkinson's disease", "Parkinson disease", "PD", "LRRK2", "GBA1", "alpha-synuclein", "synucleinopathy", "Lewy body"
- Phase filter: Early Phase 1, Phase 2, Phase 2/3, or pivotal Phase 3 trials only
- Sponsor filter: Industry-sponsored programs (competitive intelligence) or all sponsors including NIH, Michael J. Fox Foundation-funded academic studies
- Status filter: Recruiting only, all active studies, or any status including completed/terminated
What DataLookout adds to ClinicalTrials.gov
ClinicalTrials.gov RSS feeds tell you that a study record was updated. DataLookout compares each record against the previous day across 13 tracked fields and tells you which one changed, with the old and new values, for every Parkinson's Disease trial on your watchlist. Each change is marked Stopped, Notable or Minor, so a trial being terminated does not read the same as a few sites being added.
Who uses Parkinson's disease trial monitoring
Neurology pharma business development teams
BD teams at CNS-focused pharmaceutical companies track the emerging Parkinson's pipeline to identify licensing, co-development, and acquisition opportunities. A new Phase 1 alpha-synuclein antibody program from a well-capitalized biotech is material intelligence. Knowing the day it's registered, and being able to track its progression, gives BD teams a competitive edge.
Biotech investors and CNS-focused analysts
Investors covering neurology track clinical trial registrations as leading indicators of pipeline advancement. A Phase 3 initiation in a validated target like LRRK2 inhibition can precede a major financing event or partnership announcement by many months.
Clinical research organizations (CROs) with neurology practices
CROs specializing in neurology track new PD trial registrations to identify programs entering the active clinical phase, sponsors who will need site selection, patient recruitment, and data management support for complex CNS trials.
Patient advocacy organizations and foundations
Organizations like the Parkinson's Foundation and Michael J. Fox Foundation track new recruiting trials to connect patients with relevant clinical trial opportunities and monitor the overall health of the research pipeline.
Ready to automate your Parkinson's disease trial monitoring?
free plan, no credit card required.
Start FreeFrequently asked questions
How current is the Parkinson's disease trial data?
Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest. ClinicalTrials.gov is updated continuously as sponsors register new studies or submit protocol amendments.
Can I track disease-modifying and symptomatic trials separately?
Yes. On Pro ($49/month, or $490/year), you can create up to 10 sponsor and 10 disease watchlists. For example: one profile for disease-modifying programs (alpha-synuclein, LRRK2, GBA1 keywords), another for symptomatic relief trials, and a third for gene/cell therapy first-in-human studies.
Does DataLookout cover atypical parkinsonism: PSP, MSA, LBD?
Yes, you can configure keywords for progressive supranuclear palsy (PSP), multiple system atrophy (MSA), Lewy body dementia (LBD), and corticobasal syndrome. These related synucleinopathies are all registered on ClinicalTrials.gov and searchable within the same platform.
Does DataLookout cover international Parkinson's disease trials?
ClinicalTrials.gov includes internationally conducted trials when the sponsor registers them. Major industry-sponsored Phase 2/3 PD trials, which frequently include European and global sites, are generally registered and included.
1099 active trials, 644 recruiting.
Industry sponsors run 156 of these trials. The rest are run by universities, hospitals, government bodies and other non-commercial sponsors. The table below lists the 5 largest of 107.
| Top industry sponsor | Active trials |
|---|---|
| InSightec | 10 |
| AbbVie | 9 |
| iRegene Therapeutics Co., Ltd. | 6 |
| Roche / Genentech | 4 |
| AskBio Inc | 3 |
| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| Comparison of Vestibular and Dual-Task Rehabilitation in Parkinson's Disease NCT07277205 | Recruiting | Recruitment opened | 2026-10-10 |
| Wearable for Assessing Tremor and Continuous Health in Parkinson's Disease and… NCT07787299 | Recruiting | Start date pushed from Sep 1, 2026 to Nov 1, 2026 | 2026-10-10 |
| Passive Versus Active Music Therapy Parkinson's Disease NCT07661524 | Not Yet Recruiting | Start date pushed from Oct 1, 2026 to Nov 1, 2026 | 2026-10-09 |
| Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of… NCT05824728 | Active, Not Recruiting | Enrollment closed, study ongoing | 2026-10-08 |
| Kinematic and Neural Dynamics of Postural Instability in Parkinson's Disease NCT06405334 | Recruiting | Primary endpoint(s) modified | 2026-10-07 |
Each trial page shows every change DataLookout has recorded for that trial.
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top 2 trials), the weekly report (top 3 trials). No credit card.
Pro, $49/month or $490/year: 10 sponsor + 10 disease watchlists, 10 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list, Completions calendar, the full weekly report, landscape reports, CSV export.